<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Results from these animal studies also appear to mirror some of the clinical observations in SARS-CoV infected patients: the development of acute respiratory disease coincides with antiviral IgG seroconversion in 80% of patients (Peiris 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR26">2003</xref>). In addition, it was found that patients who developed the anti-S-neutralizing antibody faster had a higher chance of dying from the disease; it took an average of only 14.7 days for the deceased patients to reach their peak levels of neutralizing antibody activities, as opposed to 20 days for the recovered patients (Zhang 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR35">2006</xref>).
</p>
